Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Hereditary Angioedema Industry Expected To Reach By 2029, Starting From 2025 Levels?
The hereditary angioedema market size has witnessed robust growth in recent years. It is projected to increase from $2.62 billion in 2024 to $2.81 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.4%. The expansion observed in the historic period can be ascribed to the increasing prevalence of hereditary angioedema, heightened investment in research and development activities, a rising volume of drug approvals, increasing product approvals, and growing disposable income.
The hereditary angioedema market is anticipated to witness substantial growth over the next few years, with projections indicating it will reach $3.84 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period can be attributed to the increasing prevalence of rare diseases, greater medical expenditure, rising support from non-profit organizations, heightened awareness of hereditary angioedema, and increased emphasis on earlier diagnoses. Significant trends for the upcoming period include advancements in technology, the development of innovative therapies, the introduction of new drugs, enhanced diagnostic tools, and progress in genetic testing.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp
What Are The Main Drivers Boosting The Hereditary Angioedema Industry’s Expansion?
The increasing occurrence of rare diseases is anticipated to fuel expansion in the hereditary angioedema market moving ahead. Rare diseases, also referred to as orphan diseases, are medical conditions impacting a small segment of the population. This rise in rare disease prevalence stems from various factors, including advancements in medical research, shifts in population demographics, and environmental influences. Hereditary angioedema (HAE) stands out as a notable rare disease, underscoring the necessity for specialized treatments and public awareness given its potentially fatal swelling episodes. Its infrequent occurrence and genetic basis necessitate early diagnosis and focused therapies for effective management and better patient results. For example, in June 2022, information from Rare Disease Advisor, a US-based online resource for healthcare professionals, indicated that hereditary angioedema (HAE) affects around 1 in 50,000 individuals, with prevalence estimates varying from 1 in 10,000 to 1 in 150,000. Annually in the United States, HAE episodes lead to roughly 15,000 to 30,000 emergency room visits. Consequently, the increasing prevalence of rare diseases is fueling the expansion of the hereditary angioedema market.
What Are The Major Segments Identified In The Hereditary Angioedema Market?
The hereditary angioedemamarket covered in this report is segmented –
1) By Type: Hereditary Angioedema Type I; Hereditary Angioedema Type II
2) By Treatment Type: Prophylaxis; On-demand
3) By Drug Class: C-1 Esterase Inhibitors; Bradykynin Receptor Antagonist; Kallikrein Inhibitors; Other Drug Classes
4) By Route Of Administration: Subcutaneous; Intravenous; Oral
5) By Distribution channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency; Low C1-Inhibitor Levels; Reduced C1-Inhibitor Function
2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels; Dysfunctional C1-Inhibitor; Genetic Mutations In SERPING1 Gene
Which Ongoing Trends Are Expected To Shape The Hereditary Angioedema Market Outlook?
Leading companies in the hereditary angioedema market are actively developing innovative products, such as oral plasma kallikrein inhibitors, to offer patients more convenient and effective on-demand treatment options. These oral plasma kallikrein inhibitors are medications designed to block plasma kallikrein, thereby preventing excessive bradykinin production, and are primarily utilized for managing hereditary angioedema. For instance, in September 2024, KalVista Pharmaceuticals, Inc., a pharmaceutical company based in the US, announced the FDA’s acceptance of its new drug application (NDA) for sebetralstat. This investigational oral plasma kallikrein inhibitor is intended for the on-demand treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older. Sebetralstat introduces a new treatment approach by targeting and inhibiting plasma kallikrein activity. The acceptance of the NDA marks a significant milestone toward potential approval and commercialization.
Which Global Market Leaders Are Shaping The Future Of The Hereditary Angioedema Sector?
Major companies operating in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report
What Are The Key Regional Factors Influencing The Hereditary Angioedema Market Growth?
North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Hereditary Angioedema Market Report:
https://www.thebusinessresearchcompany.com/customise?id=22002&type=smp
Browse Through More Reports Similar to the Global Hereditary Angioedema Market 2025, By The Business Research Company
Hereditary Cancer Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Hereditary Angioedema Therapeutics Global Market Report 2025
Hereditary Breast And Ovarian Cancer Syndrome Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model